Tracking the Pandemic
A clinical trial tracker aims to encourage international collaboration on COVID-19
Maryam Mahdi | | Quick Read
“COVID-19 has created extreme uncertainties – a dearth of historical information combined with the need for safety, statistical rigor, and speed has prompted the rapid surge in the generation of clinical data,” says Edward Mills, Vice President of Real-World Evidence and Senior Principal Scientist at Cytel, a provider of advanced analytics and statistical software solutions to the life sciences sector.
But the volume of new data being produced presents a significant problem: information is scattered across multiple platforms, making it challenging to comparatively measure treatment effects across trials. Attempting to pull this data into one platform, Cytel – in collaboration with the Bill and Melinda Gates Foundation – has created a global, open-access COVID-19 clinical trial tracker.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.